Sun Pharmaceutical Industries today signed a pact with International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop a novel botanical drug for treatment of dengue.
The drug has some presence of ‘unknown impurity’, which was manufactured at the company’s Halol facility in Gujarat Around 3.8 lakh cartons of an osteoporosis drug manufactured by Sun Pharmaceutical Industri
The agreement involved transfer of these two marketing divisions, along with employees to Strides, for Rs 165 crore Sun Pharmaceutical Industries has completed the process of selling two divisions of erstwhile Ranbaxy Laborat
NCDs will be listed on BSE under two series Sun Pharmaceutical Industries has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. “Sun Pharma Laboratories, a wholly-ow
The company expects a re-inspection by US FDA Sun Pharmaceutical Industries has received a warning letter from the US FDA as a result of the September 2014 inspection, for its facility located at Halol, Gujarat. Sun Pharma re
Adopts novel approach towards development of a treatment for glioblastoma, a lethal form of brain cancer Sun Pharmaceutical Industries has entered into a tripartite research and option agreement with Israel-based Weizmann Ins
Drug major Sun Pharmaceutical Industries today reported 46.02 per cent dip in its consolidated net profit at Rs 1,106.66 crore for the second quarter...
The acquisition was completed by means of a short-form merger under Delaware law Sun Pharmaceutical Industries has acquired InSite Vision Incorporated. The acquisition was completed by means of a short-form merger under Delaw
Sun Pharmaceutical is seeking approval of its shareholders through a postal ballot earmarking of up to Rs 50,000 crore for the purpose of acquisitions or providing loans, among others.
Ranbaxy Pharmaceuticals along with its partners, Cipher Pharmaceuticals and Galephar Pharmaceutical Research have entered into a settlement agreement with Actavis Group Sun Pharmaceutical Industries announced that Ranbaxy Pha
The tender offer will expire on October 27, 2015, at 12:00 midnight New York City time Sun Pharmaceutical Industries has commenced a tender offer through its indirect wholly-owned subsidiary, Thea Acquisition Corporation, for
The agreement involves transfer of Ranbaxy’s Solus and Solus Care divisions, along with employees to Strides for a consideration of Rs 1,650 million Sun Pharmaceutical Industries and Strides Arcolab have entered into a defi
